The Effectiveness of BreatheMAX Breathing Device on Secretion Clearance (ESMOSC)

March 22, 2010 updated by: Khon Kaen University

The Effectiveness of BreatheMAX Breathing Device on Airway Secretion Clearance in Patients With Ventilatory Dependence

The purpose of this study is to determined effects of BreatheMAX on secretion clearance.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

14

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Khon Kaen
      • Muang, Khon Kaen, Thailand, 40002
        • Recruiting
        • Pulmonary research room of physical therapy department, Faculty of associated medical sciences, Khon Kaen University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 85 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • One sign of secretion accumulation in bronchi
  • Stable cardiopulmonary function
  • Good consciousness and good co-operation

Exclusion Criteria:

  • Massive hemoptysis
  • Pneumothorax (untreated)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: breathing exercise
BreatheMAX breathing device is Water pressure Threshold Bottle. The level of water in the cylinder determines the load for treatment. In the treatment using 20% PNIP (Peak negative inspiratory pressure) was performed with 6-10 breaths/set; 10 set/day
secretion clearance, breathing exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
secretion wet weight (gram)
Time Frame: Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)
Airway mucus secretion was collected for three hours before and ten hours after treatment based on an auditory airway secretion sound and collected again at 02.00-07.00 am.The mucus secretion was collected by sterile suctioning technique via tracheostomy tube without adding any saline or sterile water.
Three hours before, ten hours after treatment and night-time (02.00-07.00 am.)
viscosity of secretion
Time Frame: Three hours before and after treatment
The secretion were collected in three hours before and after treatment, It were measured viscosity by First The mucus was gently homogenized by tissue grinder 5 ml (Cw11-205, Cowie, UK) for six minute at 37 degree celsius Second using Micro-Oswald viscometers with a capillary diameter of 0.77 mm for viscosity measure at same temperature in each sample(before and after).
Three hours before and after treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate (beat/min)
Time Frame: Before, during breathing exercise with device and immediate after treatment
Heart rate was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between ste for 1 minute)
Before, during breathing exercise with device and immediate after treatment
Oxygen saturation (%SpO2)
Time Frame: Before, during breathing exercise with device and immediate after treatment
Oxygen saturation was monitored before, during and immediate after breathing exercise with BreatheMAX (6-10 beats/set, 10 set/day and rest between set for 1 minute)
Before, during breathing exercise with device and immediate after treatment
Respiratory rate (times/min)
Time Frame: In rest interval between set (1 minute)
Respiratory rate was measured by manual for 1 minute before, rest interval between set and immediate after breathing exercise with device (during the patients reconnection mechanical ventilation)
In rest interval between set (1 minute)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Sujittra Kluayhomthong, Bachelor, Physical Therapy department, Faculty of Associated Medical Sciences, Khon Kaen university
  • Study Director: Chulee CU Jones, Philosophy, Physical Therapy Department, Faculty of Associated Medical Sciences, Khon Kaen university, Thailand
  • Study Director: Wilaiwan Khrisanapant, Philosophy, Department of physiology, Faculty of medicine, Khon Kaen university

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2009

Primary Completion (Actual)

December 1, 2009

Study Registration Dates

First Submitted

January 7, 2010

First Submitted That Met QC Criteria

March 22, 2010

First Posted (Estimate)

March 23, 2010

Study Record Updates

Last Update Posted (Estimate)

March 23, 2010

Last Update Submitted That Met QC Criteria

March 22, 2010

Last Verified

January 1, 2010

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Disease

Clinical Trials on BreatheMAX breathing device

Subscribe